KIYATEC Secures CAP Accreditation and NY State Approval for Revolutionary 3D Cancer Diagnostic Platform
核心洞察
KIYATEC (搜索)'s laboratory has received prestigious College of American Pathologists (CAP) accreditation and New York State approval for its innovative 3D Predict (搜索) cancer diagnostic test, validating its quality standards and clinical utility.
The company's proprietary 3D cell culture platform represents a breakthrough in functional precision oncology, offering the first evidence-based correlation between therapeutic response predictions and actual patient outcomes.
The 3D Predict (搜索) platform brings new hope for high-grade glioma (搜索) patients, including those with glioblastoma (搜索), by providing oncologists with patient-specific treatment response predictions to guide therapy decisions.
KIYATEC (搜索) Inc., a pioneer in patient-specific cancer diagnostics, has achieved two major regulatory milestones that strengthen its position in the precision oncology landscape. The company's laboratory has secured both the prestigious College of American Pathologists (CAP) accreditation and New York State approval for its innovative 3D Predict (搜索) diagnostic platform.
Advancing Laboratory Excellence
The CAP accreditation, widely regarded as the gold standard in laboratory quality assurance, validates KIYATEC (搜索)'s commitment to maintaining exceptional standards in laboratory operations. This certification, combined with the company's existing CLIA certification (Certificate #42D2130169) and established CPT Code (0248U), reinforces the clinical reliability and accessibility of their diagnostic technology.
Revolutionary Approach to Cancer Treatment Planning
KIYATEC (搜索)'s proprietary 3D cell culture platform stands out as the only technology supported by peer-reviewed evidence demonstrating correlation between its therapeutic response predictions and actual patient outcomes. This breakthrough represents a significant advancement in functional precision oncology, moving beyond traditional one-size-fits-all approaches to truly personalized treatment strategies.
Impact on High-Grade Glioma Treatment
The platform's approval holds particular significance for patients battling high-grade gliomas, including glioblastoma (搜索), where therapeutic advances have remained stagnant for decades. The 3D Predict (搜索) Glioma (搜索) test provides oncologists with crucial insights for treatment decision-making, marking the first meaningful progress in this challenging area of oncology in years.
Clinical Implementation and Future Directions
"We're thrilled to see our 3D Predict (搜索) platform gaining this recognition," stated Eric Perreault, CEO of KIYATEC (搜索). "These approvals mean so much because they're not just about validating our science – they're about making a real difference in patients' lives. I'm passionate about ensuring that more patients and their doctors have access to the personalized insights these tests provide."
The platform's unique ability to predict individual patient responses to specific cancer therapies represents a paradigm shift in oncology diagnostics. By analyzing live tumor cells in a three-dimensional environment, KIYATEC (搜索) provides oncologists with actionable data to optimize treatment selection and potentially improve patient outcomes.